Despite the impact of the COVID-19 pandemic on sales of its key products, most notably the hyperkalemia therapy Veltassa, Vifor Pharma Group has posted a healthy set of financials for 2020 and is targeting a couple more deals this year to cement its strength across the nephrology space.
Speaking to Scrip ahead of the Swiss firm's full-year results announcement, CEO Stefan Schulze said the aim was to complete...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?